Tags » PTAB

Posts
In 2019, the Patent and Trial Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) issued a decision in the first inter partes review of a cannabis related patent (Insys Development Company, Inc. v. GW Pharma Limited and Otsuk (More)
As increasing numbers of U.S. states have legalized both medical and adult-use cannabis, another set of Schedule 1 controlled substances - psychedelics - has begun to emerge from the shadows. Psychedelics such as psilocybin, lysergic acid diethylamid (More)